Home › Research › Treatments
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV.. Lancet (London, England), 2002-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. Galantamine amplifies the acetylcholine response by inhibiting acetylcholinesterase and modulating nicotinic receptors. It has shown broad, sustained benefits in patients with Alzheimer's disease. We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease. Methods Eligible patients were randomly assigned galantamine 24 mg/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial. Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input [CIBIC-plus]). Secondary endpoints included assessments of activities of daily living and behavioural symptoms. Patients were monitored for adverse events. Analyses were on the basis of observed case or last observation carried forward. Findings Galantamine showed greater efficacy than placebo on ADAS-cog (galantamine change -1.7 [SE 0.4] vs placebo 1.0 [0.5]; treatment effect 2.7 points; p Interpretation Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients.
What this study adds
Evidence grade: Low
This is a trial of 396 participants. In this 6-month double-blind trial, 592 people with probable vascular dementia or Alzheimer's disease plus cerebrovascular disease were randomly given galantamine 24 mg a day (396) or placebo (196). On the ADAS-cog thinking test, the galantamine group improved by 1.7 points while the placebo group worsened by 1.0, a 2.7-point difference.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002). Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (London, England). https://doi.org/10.1016/s0140-6736(02)08267-3
Vancouver
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (London, England). 2002. doi:10.1016/s0140-6736(02)08267-3. PMID: 11965273.
BibTeX
@article{erkinjuntti2002-11965273,
author = {Erkinjuntti, T. and Kurz, A. and Gauthier, S. and Bullock, R. and Lilienfeld, S. and Damaraju, C. V.},
title = {{Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial}},
journal = {Lancet (London, England)},
year = {2002},
doi = {10.1016/s0140-6736(02)08267-3},
pmid = {11965273},
url = {https://doi.org/10.1016/s0140-6736(02)08267-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input [CIBIC-plus]).
- Secondary endpoints included assessments of activities of daily living and behavioural symptoms.
- Patients were monitored for adverse events.
- Analyses were on the basis of observed case or last observation carried forward.
- Findings Galantamine showed greater efficacy than placebo on ADAS-cog (galantamine change -1.7 [SE 0.4] vs placebo 1.0 [0.5]; treatment effect 2.7 points; p<0.0001) and CIBIC-plus (213 [74%] vs 95 [59%] patients remained stable or improved, p=0.0001).
Why it matters
In this 6-month double-blind trial, 592 people with probable vascular dementia or Alzheimer's disease plus cerebrovascular disease were randomly given galantamine 24 mg a day (396) or placebo (196). On the ADAS-cog thinking test, the galantamine group improved by 1.7 points while the placebo group worsened by 1.0, a 2.7-point difference. The authors report benefits across "all key areas of cognitive and non-cognitive abilities", but the copy of the abstract we hold is cut off before those other results, so only the thinking-test result can be checked here, and it describes symptoms over 6 months, not a cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants396
- Evidence strengthLow
How this study scored 73/100
Published in a top-tier journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Lancet (London, England)) |
| Journal's citation record | 4 / 4 | The Lancet: journal h-index 1,205 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 2 / 4 | 396 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 759 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 29.2 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 6 / 6 | Cited 48.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 36 other studies in this library |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author ChandrasekharRao Venkata Damaraju: h-index 27 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11965273) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
36 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.